AIM
SUPN icon

Aigen Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Aigen Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,343
Closed -$226K – 823
2022
Q4 		$226K Buy
+6,343
New +$220K 0.03% 425
2020
Q4 		– Sell
-17,429
Closed -$363K – 1034
2020
Q3 		$363K Buy
17,429
+4,613
+36% +$105K 0.05% 482
2020
Q2 		$304K Buy
+12,816
New +$283K 0.04% 615
2020
Q1 		– Sell
-7,213
Closed -$171K – 1551
2019
Q4 		$171K Buy
+7,213
New +$175K 0.03% 590

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aigen Investment Management's SUPN Position: Q1 2023 in Review

Aigen Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 6,343 shares — an estimated $226K sold.

Aigen Investment Management first reported a position in SUPN in Q4 2019 and held it in 4 quarters. The position peaked at $363K in Q3 2020. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • Aigen Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Aigen Investment Management sold 6,343 Supernus Pharmaceuticals shares in Q1 2023, an estimated $226K.
  • Aigen Investment Management first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Aigen Investment Management's Supernus Pharmaceuticals position peaked at $363K in Q3 2020.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on Aigen Investment Management's 13F filing for Q1 2023, filed 15 May 2023.